Efficacy of Qingfei Paidu Decoction on Patients with COVID-19 Pneumonia in Wuhan, China: A Propensity Score Matching Study

Table 1

Characteristics of patients with COVID-19 pneumonia.

Variables	QPD	NoQPD	SMD
n	239	522
Sex
Female (%)	120 (50.2)	251 (48.1)	0.043
Age (median [IQR])	60.00 [51.00–66.00]	62.00 [50.00–70.00]	0.022
Symptoms
Fever	192 (80.3)	439 (84.1)	0.099
Dizziness	27 (11.3)	51 (9.8)	0.050
Fatigue	128 (53.6)	278 (53.3)	0.006
Nausea	35 (14.6)	51 (9.8)	0.149
Diarrhea	46 (19.2)	100 (19.2)	0.002
Myalgia	62 (25.9)	111 (21.3)	0.110
Abnormality of mentality	9 (3.8)	72 (13.8)	0.360
Headache	18 (7.5)	26 (5.0)	0.105
Abdominal pain	13 (5.4)	20 (3.8)	0.077
Dyspnea	179 (74.9)	367 (70.3)	0.103
Cough	188 (78.7)	395 (75.7)	0.071
Sputum	105 (43.9)	214 (41.0)	0.059
Chest pain	14 (5.9)	22 (4.2)	0.075
Comorbidity
Hypertension	45 (18.8)	105 (20.1)	0.032
Diabetes	21 (8.8)	18 (3.4)	0.224
Coronary heart disease	13 (5.4)	36 (6.9)	0.061
COPD	1 (0.4)	3 (0.6)	0.022
Cancer	6 (2.5)	14 (2.7)	0.011
Chronic renal disease	0 (0.0)	2 (0.4)	0.088
Cerebrovascular disease	5 (2.1)	12 (2.3)	0.014

SMD >0.1 indicates a difference in baseline characteristics between both groups. QPD, Qingfei Paidu decoction; SMD, standardized mean difference; IQR, interquartile range; COPD, chronic obstructive pulmonary disease.